



Bayer 9776-KGB
Le A 30 218-US Bu/MI

#5

D. Williams
7/18/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hanno Wild et al
Serial No. : 08/765,012
Filed : December 19, 1996
For : HIL-4 MUTANT PROTEINS USED AS ANTAGONISTS OR
PARTIAL AGONISTS OF HUMAN INTERLEUKIN 4
Art Unit : 1806
Examiner : G. Bansal

June 23, 1997

Hon. Assistant Commissioner
for Patents
Washington, D. C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR § 1.56 and § 1.97(b), Applicants wish to call the attention of the Examiner to the references listed below:

- | | | | |
|----|----------------|----------|----------------|
| 1. | U.S. 5,538,884 | 07/23/96 | Dörreich et al |
| 2. | U.S. 4,640,835 | 02/03/87 | Shimizu et al |
| 3. | U.S. 4,496,689 | 01/29/85 | Mitra |
| 4. | U.S. 4,301,144 | 11/17/81 | Iwashita et al |

5.	U.S. 4,670,417	06/02/87	Iwasaki et al
6.	U.S. 4,791,192	12/13/88	Nakagawa et al
7.	U.S. 4,179,337	12/18/79	Davis et al
8.	U.S. 3,773,919	11/20/73	Boswell et al
9.	U.S. 4,485,045	11/27/84	Regen
10.	U.S. 4,544,545	10/01/85	Ryan et al
11.	U.S. 5,013,556	05/07/91	Woodle et al
12.	U.S. 5,298,410	03/29/94	Phillips et al
13.	U.S. 4,767,628	07/17/90	Hutchinson
14.	U.S. 4,619,794	10/28/86	Hauser
15.	U.S. 4,615,885	10/07/86	Nakagame et al
16.	U.S. 4,590,060	05/20/86	Ehrenfeld
17.	WO 93/10235	05/27/93	World
18.	WO 89/02922	04/06/89	World
19.	WO 87/05330	09/11/87	World
20.	DE 32 18 121	11/17/83	Germany
21.	EP 133 988	03/13/85	Europe
22.	EP 52 322	05/26/82	Europe
23.	EP 36 676	09/30/81	Europe
24.	EP 102 324	03/07/84	Europe
25.	WO 88/04667	06/1988	World
26.	Kruse et al, (1991) FEBS Lett. 286, 58-60		

27. Kikutani et al, (1986) Cell 47, 657-665
28. Yokota et al, (1986) Proc.Natl.Acad.Sci., USA 83, 5894-5898
29. Carr et al, Biochemistry 1991, 30 1515-1523
30. Weigel et al, (1989) Eur.J.Biochem. 180, 295-300
31. Flinta et al, Eur.J.Biochem. 154, 193-196 (1986)
32. Cunningham et al, Science, 244, 1081-1085 (1989)
33. Aplin et al, CRC Crit.Rev.Biochem., 259-306 (1981)
34. Hakkimuddin et al, Arch.Biochem.Biophys., 259:52 (1987)
35. Edge et al, Anal.Biochem., 118:131 (1981)
36. Win Ping Deng et al, Anal.Biochem. 200:81 (1992)
37. Thotakura et al, Meth.Enzymol. 138:350 (1987)
38. Duksin et al, J.Biol.Chem., 257:3105 (1982)
39. Maxfield et al, Polymer 16:505-509 (1975)
40. Bailey et al, Nonionic surfactants [Schick, M.J., Hrsq.] 794-821 (1967)
41. Abuchowski et al, J.Biol.Chem. 252:3582-3586 and 3578-3581 (1977)
42. Abuchowski et al, Cancer Biochem.Biophys., 7:175-186 (1984)
43. Katre et al, Proc.Natl.Acad.Sci., 84:1487-1491 (1987)
44. Goodson et al, Biotechnology, 8:343-346 (1990)
45. Remington's Pharmaceutical Sciences, 16. Auflage, Osol A., Hrsg. (1980)
(Complete Book)
46. Langer et al, J.Biomed.Mater.Res., 15:267-277 (1981)
47. Sidman et al, Biopolymers, 22:547-556 (1983)

48. Eppstein et al, Proc.Natl.Acad.Sci. USA, 82:3688-3692 (1985)
49. Hwang et al, Proc.Natl.Acad.Sci. USA, 77:4030-4034 (1980)
50. Kruse et al, EMBO J. 11, 3237 (1992)
51. Kruse et al, EMBO J. 11, 789-790 (1992)

Copies of most of these references are submitted herewith along with Form PTO-1449. Remington's Pharmaceutical Sciences (reference no. 47) is the only reference not being included because it is too large to submit.

The relevance of the listed references is as follows. Reference nos. 12, 17, 25, 50 and 51 were cited in the Search Report issued by the International Patent Office. A copy of this Search Report is also enclosed. For the Examiner's information, the designated "Y" means "particularly relevant if combined with another document of the same category".

The remaining references are cited in the specification of the present application at the following locations:

<u>Reference No.</u>	<u>Page/line</u>
1. Equivalent to DE 42 37 333	Page 2/line 13
2.	Page 3/line 13 and Page 11/line 31
3.	Page 3/line 13 and Page 11/line 31

4.	Page 3/line 13 and Page 11/line 32
5.	Page 3/line 13 and Page 11/line 32
6.	Page 3/line 13 and Page 11/line 32
7.	Page 3/line 13 and Page 11/line 32
8.	Page 15/line 25
9.	Page 16/line 17
10.	Page 16/line 17
11.	Page 16/line 21
13. Equivalent to EP 58 481	Page 15/line 25
14. Equivalent to EP 88 046	Page 16/line 16
15. Equivalent to EP 143 949	Page 16/line 16
16. Equivalent to EP 142 641	Page 16/line 16
17.	Page 1/line 8
18.	Page 9/line 15
19.	Page 11/line10
20.	Page 16/line 14
21.	Page 15/line 20
22.	Page 16/line 16
23.	Page 16/line 16
24.	Page 16/line 17
26.	Page 5/line 25
27.	Page 5/line 25

- 28. Page 5/line 32
- 29. Page 6/line 7
- 30. Page 6/lines 18-19
- 31. Page 18/line 9
- 32. Page 7/lines 9-10
- 33. Page 11/line 11
- 34. Page 11/lines 19-20
- 35. Page 11/lines 20-21
- 36. Page 17/line 13
- 37. Page 11/line 23
- 38. Page 11/line 26
- 39. Page 12/lines 12-13
- 40. Page 12/lines 13-14
- 41. Page 12/lines and 22
- 42. Page 12/line 17
- 43. Page 12/line 19
- 44. Page 12/line 20
- 45. Page 12/line 29 and Page 15/lines 1-2
- 46. Page 15/lines 23-24 and 27-28
- 47. Page 15/lines 26-27
- 48. Page 16/line 13
- 49. Page 16/line 15


The Commissioner is hereby authorized to charge the fee for consideration of this information disclosure statement, which is set forth in § 1.17(p), to Deposit Account No. 02-1445.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

SPRUNG KRAMER SCHAEFER & BRISCOE

By


Kurt G. Briscoe
Reg. No. 33,141

KGB:cg
Enc.: International Search Report
PTO-1449
References (51)
Notice of Change of Firm Name
B9776.IDS


660 White Plains Road
Tarrytown, New York 10591-5144
(914) 332-1700

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on June 23, 1997.

SPRUNG KRAMER SCHAEFER & BRISCOE

By

Date


June 23, 1997